Loading...
Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
BACKGROUND: The aim of the study was to investigate the temporary combination of anti-PD-1 plus targeted therapy followed by single targeted therapy in advanced renal cell carcinoma (RCC) as second-line therapy. METHODS: A total of 17 patients from Fudan University Shanghai Cancer Center (FUSCC) wit...
Saved in:
| Published in: | Transl Androl Urol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
AME Publishing Company
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8185682/ https://ncbi.nlm.nih.gov/pubmed/34159088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tau-21-338 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|